PT  - JOURNAL ARTICLE
AU  - McGeachan, Robert I
AU  - Keavey, Lois
AU  - Rose, Jamie L
AU  - Simzer, Elizabeth M
AU  - Chang, Ya Yin
AU  - Spires-Jones, Maxwell P
AU  - Gilmore, Mollie
AU  - Ravingerova, Natalia
AU  - Scutariu, Cristina
AU  - Taylor, Lewis
AU  - King, Declan
AU  - Tzioras, Makis
AU  - Tulloch, Jane
AU  - Booker, Sam A
AU  - Liaquat, Imran
AU  - Hindley-Pollock, Nicole
AU  - Geary, Bethany
AU  - Smith, Colin
AU  - Brennan, Paul M
AU  - Durrant, Claire S
AU  - Spires-Jones, Tara L
TI  - Evidence for trans-synaptic propagation of oligomeric tau in Progressive Supranuclear Palsy
AID  - 10.1101/2022.09.20.22280086
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2022.09.20.22280086
4099  - http://medrxiv.org/content/early/2024/02/12/2022.09.20.22280086.short
4100  - http://medrxiv.org/content/early/2024/02/12/2022.09.20.22280086.full
AB  - In the neurodegenerative disease Progressive Supranuclear Palsy (PSP), tau pathology progresses through the brain in a stereotypical spatiotemporal pattern, and where tau pathology appears, synapses are lost. We tested the hypothesis that tau pathology spreads between brain regions in PSP by moving from pre- to post-synapses. Sub-diffraction-limit microscopy of human post-mortem brain samples revealed that oligomeric tau is present in synaptic pairs in PSP, with an 80-fold increased chance of post-synapses containing tau when they oppose a tau-containing pre-synapse. In living human brain slice cultures, PSP-derived oligomeric tau was taken up by post-synapses. Synaptic engulfment by astrocytes was observed in both post-mortem brain and human brain slice cultures challenged with PSP-derived tau. These data indicate that tau pathology spreads via synapses in PSP and that astrocytes contribute to synapse loss. Targeting synaptic tau and astrocyte-mediated phagocytosis of synapses are promising targets for attenuating synaptic loss and pathology propagation in PSP.Competing Interest StatementTSJ is a scientific advisory board member of Scottish Brain Sciences, Cognition Therapeutics, and Race Against Dementia and has consulted for Jay Therapeutics, and MT is an employee of Scottish Brain Sciences.Funding StatementThis work was supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK (grant code UKDRI-Edin005). The confocal microscope was generously funded by Alzheimer's Research UK (ARUK-EG2016A-6) and a Wellcome Trust Institutional Strategic Support Fund at the University of Edinburgh. J.L. was funded by UCB Biopharma, as was the Oxford Nanoimager. M.H. and J.L. acknowledge funding from Dr. Jim Love. Dr Claire Durrant receives funding from Race Against Dementia (ARUK-RADF-2019a-001), The James Dyson Foundation, and the Alzheimer's Society (581 (AS-PG-21-006)). Dr Robert McGeachan is funded by the Wellcome Trust, as part of the Edinburgh Clinical Academic Track for Veterinary Surgeons (225442/Z/22/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Edinburgh Brain Bank ethics committee, the Academic and Clinical Central Office for Research and Development (ACCORD) and the medical research ethics committee AMREC a joint office of the University of Edinburgh and National Health Service Lothian, approval number 15-HV-016) all gave ethical approval for post-mortem tissue work. Use of living resected human tissue has been approved by AMREC and Lothian NRS Bioresource (Spires-Jones and Durrant, REC number: 15/ES/0094, IRAS number: 165488, Bioresource No SR1319). Additional Caldicott Guardian approval (CRD19080) has been obtained to receive data about the sex, age (in years), brain region the tissue was taken from and the clinical reason for surgery. The informed consent of patients was obtained using the Lothian NRS Bioresource Consent Form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon acceptance of the peer-reviewed version of this manuscript, all data spreadsheets and statistical analysis files will be available online as supplementary data. Images are available upon reasonable request. All custom software and scripts used in the study is available on GitHub at https://github.com/Spires-Jones-Lab https://github.com/Spires-Jones-Lab